Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial
- Gabriel N. Hortobagyi
- , Catherine Van Poznak
- , W. Graydon Harker
- , William J. Gradishar
- , Helen Chew
- , Shaker R. Dakhil
- , Barbara B. Haley
- , Nicholas Sauter
- , Ramon Mohanlal
- , Ming Zheng
- , Allan Lipton
Research output: Contribution to journal › Article › peer-review
159
Link opens in a new tab
Scopus
citations